

EEA Life Settlements Fund PCC Limited

Some of your questions answered about EEA Life Settlements Fund PCC Limited

Last updated: 2 August 2023

This document is meant to help you but not to replace the primary sources of information, including in particular the Information Memorandum and Supplements. You are urged to read those documents and to consult your professional adviser before making any decision in respect of the Fund.

Important Information:

This material is being issued by EEA Fund Management (Guernsey) Limited (the "Manager") (which is licensed by the Guernsey Financial Services Commission to carry on the restricted activities of promotion, subscription, dealing, management, advising and administration in connection with Category 1 Collective Investment Schemes and Category 2 General Securities and Derivatives under The Protection of Investors (Bailiwick of Guernsey) Law 1987 as amended), and has been approved for issue in the UK by EEA Fund Management Limited (which is authorised and regulated by the Financial Conduct Authority (the "FCA")).

EEA Life Settlements Fund PCC Limited (the "Fund") is an unregulated collective investment scheme as contemplated by the Financial Services and Markets Act 2000 and, accordingly, its promotion in the UK is restricted by law. It may be promoted by a UK authorised person in accordance with Section 238 of the UK Financial Services and Markets Act 2000 Act and/or the FCA Rules. Any person who is not an authorised person may not distribute it to any other person. This document may not be given to, or relied or acted upon by, any other person.

As at the date of this document, the Fund has not been approved, notified or registered in accordance with Article 42 of the EU Alternative Investment Fund Managers Directive (2011/61/EU) for marketing to professional investors in any member state of the European Economic Area. Such approval, notification or registration will not be made or sought in the future since the Fund is closed to further subscriptions and will not, therefore, be marketed to professional investors in the European Economic Area.

The Fund is closed to further subscriptions and neither this document nor the Fund's Information Memorandum and Supplements (which, amongst other things, set out the risk factors associated with an investment in the Fund) constitute a direct or indirect offering or placement of shares or any other opportunity to invest in the Fund. Nothing contained in this note is to be construed as providing or offering investment, legal, accounting, tax or other advice and nothing should be relied on as such. The value of investments may go down as well as up and may be affected by changes in rates of exchange. Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, express or implied, is made regarding performance. Investments in the Fund do not provide capital guarantees like a deposit account and are not readily accessible. The rules on taxation can change and/or the tax treatment of the Fund could be challenged. Whilst all reasonable efforts have been made to ensure this document is accurate and up to date, no representations or warranties, either express or implied, are given as to the reliability, accuracy or completeness of the information contained in this note. Any opinions expressed are judgments at the time of writing and are subject to change without notice. To the extent permitted by law or regulation, no liability is accepted for any damage or loss, including without limitation loss of profit whether direct, indirect or consequential, in respect of the use of this material.

Introduction

This document is designed to answer some of your questions and help you understand the latest news relating to the Fund. The guide should be read in conjunction with the Fund's Information Memorandum, Supplements and Articles of Incorporation. You should speak to your professional adviser before taking any action.

Copies of the Information Memorandum, Supplements and Articles of Incorporation, together with the Fund's monthly Fact Sheets, quarterly Portfolio Statistics (which indicates the latest update on performance and maturity projections), Maturity Schedules and other Fund updates are available online at <http://www.eeafmg.com/>

Shareholder Questions and Answers

1. Can I redeem my Shares?

As noted in the Fund's update to Shareholders on 31 March 2023, there are a number of issues which the Board is currently reviewing as matters of priority, including, among other matters, the US Proceedings. These matters could have implications that might affect the Company and its Shareholders.

Redemptions have been suspended in accordance with the constitutional documentation and scheme particulars for the Fund.

Redemption requests may still be submitted as normal.

Redemption requests will be logged in order that they are received and will be queued by reference to the quarterly redemption date in respect of which they have been received.

Please refer to section 16 for further information.

Process in respect of the Continuing Cells:

The relevant Supplements provide that Continuing Shares are redeemable on the last working day of each calendar quarter, subject to at least 95 days' written notice of any redemption request. However, the Fund's board of directors (the "Board") has exercised its discretion to change the timing of future Redemption Days from the last working day of each calendar quarter to the first working day after each calendar quarter. The Valuation Point for the purposes of redemptions will continue to be 23.59 hours (Guernsey time) on the last business day of each calendar quarter. The timings for the next three Redemption Days are therefore as follows:

Redemption Day 2 October 2023 – deadline for receipt of redemption requests 17.00 hours (Guernsey time), 29 June 2023.

Redemption Day 2 January 2024 – deadline for receipt of redemption requests 17.00 hours (Guernsey time), 29 September 2023.

Redemption Day 2 April 2024 – deadline for receipt of redemption requests 17.00 hours (Guernsey time), 29 December 2023.

Further details of the redemption process, and the Board's powers to restrict redemptions, are set out in the Fund's Information Memorandum, Supplements and Articles of Incorporation. A Redemption Request Form is available at www.eeafmg.com/eea-life-settlements-fund. If you have any further questions about the redemption process, please contact the Fund's administrator, Apex Fund Service (the "Administrator") by emailing them at eea@apexgroup-fs.com.

In respect of the Run-Off Cells:

Run-Off Shares cannot be redeemed at a Shareholder's election. Surplus cash (if any) generated within each Run-Off Cell from the policies that mature or are sold (after prudent provision has been made to cover anticipated premiums and other necessary costs) will be distributed among shareholders in that Run-Off Cell, by way of compulsory redemption of a portion of each holder's Run-Off Shares or otherwise, until proceeds from the final policy held

in respect of that Run-Off Cell have been returned to Run-Off Shareholders. Run-Off Shareholders will continue to receive periodic distributions, by way of compulsory redemption of a portion of each holder's Run-Off Shares or otherwise, as and when cash levels permit. Please refer to the Fund's Information Memorandum and Supplements, which contain full details of this process.

For further information on distributions to Run-Off Shareholders, see section 5 below.

2. Please provide an update to Continuing Shareholders in respect of the 3 July 2023 Redemption Day?

As explained above, Redemptions have been suspended. Please refer to section 16 for further information.

3. How is Available Cash calculated?

"Available Cash" means cash held by a Cell after deduction for any accrued fees and expenses but, for the avoidance of doubt, excludes unsettled cash from policy maturities and cash required to pay the premia on Current Underlying Investments from time to time attributable to the Cell for a specified period which will be retained by the relevant Cell or one or more subsidiaries of the Fund. In calculating the level of Available Cash for each Cell at 30 June 2023, the directors excluded an amount consisting of cash and receivables to pay the premia on Current Underlying Investments for 16 months which means that \$15.91m in aggregate was excluded across all Cells when determining the level of Available Cash.

4. As a Run-off Shareholder, how long will it be before I receive the final proceeds from the maturity or sale of the final policy?

It is impossible to say with certainty how long it will be before Run-Off Shareholders receive the final proceeds from the maturity or sale of the final policy held by the relevant Run-Off Cells. Although there is no guarantee that actual maturities will happen as projected, the Manager does publish maturity projections in the quarterly Portfolio Statistics, which are available at www.eeafmg.com.

5. When will another distribution be made to Run-Off Shareholders?

The Fund distributed in aggregate approximately \$10 million to those persons registered as holders of Run-Off Shares as at 10 January 2023.

The Board make a further distribution to holders of Run-Off Shares as cash levels and factors relating to the suspension of Redemptions permit.

6. Can I switch my shareholding from one Cell to another Cell?

No, switches between Cells are not possible.

7. Can I transfer my Shares?

It is possible to transfer shares in the Fund in certain circumstances. You will need to contact the Administrator by emailing them at eea@apexgroup-fs.com or calling them on +44 (0)1481 741250 to discuss what is required if you wish to transfer your Shares.

8. Does the Fund intend to purchase policies for the Continuing Cells?

The Information Memorandum and Supplements state that Available Cash attributable to a Continuing Cell that is not used to fund redemption requests and/or other expenses will be reinvested to provide exposure to policies with similar characteristics to those currently held by the Fund. No amounts have yet been reinvested and Available Cash attributable to a Continuing Cell will not be reinvested whilst there are redemption requests outstanding for that relevant Cell.

9. Does the Fund have the right to sell policies?

Yes, the Fund's investment policy, which is set out in the Information Memorandum and Supplements, provides the Fund and the Manager with the flexibility to sell policies to third parties before maturity as part of portfolio management. For example, the Fund exercised its right to sell policies in September 2015 when it sold 187 policies (see www.eeafmg.com for the schedule identifying these policies) for approximately \$130m and again in April 2017 when it sold three policies (policy numbers 15884, 14475 and 16426) for \$663,500.

10. What performance is expected?

As you will appreciate, it is not possible to project future returns with any certainty, although the Board will of course be monitoring the maturity experience of the portfolio and will continue to provide updates to shareholders on Fund performance and maturity projections in the quarterly Portfolio Statistics.

11. How are policy maturities performing in comparison with earlier projections?

The quarterly Portfolio Statistics document contains Maple Life's maturity projections as at 31 December 2022, which are based on an assumed continuation of historic Fund mortality experience. The Manager's quarterly commentary provides details of reported maturities in comparison with those projections.

12. What is being done to manage costs?

The Manager and the Board have been working hard to manage the Fund's costs.

In May 2015, the Manager confirmed that it would pay the future administration fees of the Administrator, thus reducing the fees paid by the Fund.

The Fund has also benefited from a reduction in charges for registrar services following the appointment of a new administrator and registrar which became effective on 1 February 2016.

The Board and the Manager agreed in September 2016 to cease production of the Fund's unaudited interim report. The Fund is not obliged to produce an interim report and it now considers that the cost of its production outweighs any benefit to Shareholders. The Manager continues to provide substantial information relating to the Fund as explained in section 17 below.

In November 2015, the Investment Adviser agreed to reduce its NAV-based fee so that it no longer received a fee based on the NAV attributable to the Fund's cash assets. Both the Manager and the Investment Adviser also agreed to waive their entitlement to any future performance fee. In September 2018, it was agreed that the Investment Adviser's fee would be changed to a fixed fee of \$50,000 per month, to provide the Fund with more certainty regarding the continuance of the services provided by the Investment Adviser.

The Board and the Manager will continue to monitor the Fund's costs.

13. Some policies have expired without value. Could this happen again?

17 policies, with a total death benefit of around US\$27.05m, have expired since the start of 2014 due to the underlying insureds reaching the age at which their policy automatically terminates. The value of these policies had been written down over several years thus reducing the impact on the Fund's NAV.

14. What is the situation regarding the currency hedge?

There is no obligation to reinstate the currency hedge, but the Manager will consider doing so if commercially reasonable terms can be found.

It is worth mentioning that a currency hedge requires cash to be set aside to settle positions, and a counterparty would also expect collateral (more cash) to be posted. These requirements would reduce the amounts of cash available for distribution (in relation to Run-Off Shares) and reinvestment (in relation to Continuing Shares).

15. What are your views on the adverse publicity about the Fund?

We are obviously concerned when we read inappropriate or ill-informed comments in the press, particularly from persons who are neither regulated financial advisers nor experts in the area of life settlements.

Many Shareholders may not be aware of these but they are seen by some, and in particular they are noticed by relevant third parties, such as those considering buying policies from the Fund. We recognise that such comments cause unnecessary alarm and anxiety to some of our Shareholders. Such behaviour is also regrettable as it risks, amongst other things, having an adverse effect on the sale prices of policies, and can therefore be detrimental to the interests of both the Fund and Shareholders more generally.

The Manager provides a substantial amount of information regarding the Fund and will continue to encourage constructive dialogue with Shareholders and their advisers. Shareholders are strongly encouraged to make their own investment decisions based solely on information provided by the Fund and/or any advice provided by their independent financial advisers.

It should be noted that, for the avoidance of doubt, the Fund and Manager strongly dispute any suggestion that the Fund is not being handled properly or in investors' interests. This document already details much of the work undertaken by both the Manager and the Board, including in relation to the restructuring of the Fund which became effective on 1 January 2014, the sale of policies in 2015 and the ongoing drive to manage fees. The Manager, together with the Investment Adviser, is regularly reviewing the policies held by the Fund and considering opportunities to enhance returns.

16. What are your comments regarding the complaint made by Coventry Capital?

Whilst it is not our practice to comment on active litigation matters, we note that EEA Life Settlements, Inc. and Messrs Piscaer and Patel have made clear that they categorically reject the allegations contained in the Complaint made by Coventry Capital on 28 September 2017 entitled Coventry Capital US LLC v. EEA Life Settlements, Inc. et al. They are of the view that the Complaint is simply a tool being used by Coventry Capital to attempt to negotiate through litigation and that the allegations are wholly without merit, and they look forward to vindication of their actions.

The below Q&As were updated in May 2023:

a. What has prompted the US proceedings in Coventry Capital US LLC v EEA Life Settlements Inc., & others (the US Proceedings)?

The US Proceedings relate to a failed negotiation in 2017 between EEA Life Settlements Inc. (**EEA Inc.**) and Coventry Capital US LLC (**Coventry**), for the sale of portfolio of investments in life insurance policies. The parties entered into a letter of intent, under which they agreed to negotiate further in good faith to explore a potential sale. A final agreement was never reached.

In September 2017, after negotiations broke down, Coventry filed a complaint against EEA Inc. and Vincent Piscaer and Hiren Patel (together, the **Defendants**) alleging that the 9 Defendants engaged in a pattern of conduct that undermined the negotiations with Coventry. The Defendants deny the allegations made against them.

None of EEA Life Settlements Fund PCC Limited (the **Fund**), EEA Fund Management (Guernsey) Limited (the **Manager**) or EEA Fund Management Limited (the **Marketing Agent**) are parties to the US Proceedings.

b. What is the current status of US Proceedings.

The US Proceedings have completed the discovery stage of the litigation and the parties are currently briefing motions for summary judgment, which briefing is scheduled to be completed by September 1, 2023.

c. How is legal defence of the various EEA entities being paid?

As explained in section 'a' above, the Fund, the Manager and the Marketing Agent are not defendants in the US Proceedings and are not the subject of any allegations of wrongdoing by Coventry.

EEA Inc. has successfully been claiming recovery of its legal defence costs under applicable insurance policies, under which the Fund is also an insured party. The Manager and the Marketing Agent have also successfully claimed recovery of some legal costs that they have incurred as non-parties under (different) applicable insurance policies, and to the extent that their costs have been incurred in producing documents to EEA Inc. to assist EEA Inc.'s defence of the litigation, those costs are indemnified by EEA Inc.

d. What protection do Shareholders have for loss of policies if the defence fails in the US Proceedings?

Coventry is seeking damages and/or an order that EEA Inc. be required to sell (to Coventry) some or all of the Fund's portfolio of policies. In either event, unless coverage by any applicable insurance policies is available, that order would be met out of the assets of EEA Inc. Whilst not a party to the US Proceedings, the Fund continues to take those steps which it believes to be most appropriate in the circumstances to protect the interests of its investors. The Fund will continue to keep its investors updated, where and to the extent it is appropriate to do so, with relevant information on the US Proceedings. If Shareholders have specific queries in relation to the US Proceedings they are asked to contact the Fund by email at eea@apexgroup-fs.com.

e. What is Coventry seeking under the US Proceedings?

Coventry is seeking damages in respect of alleged adviser fees incurred in negotiating the letter of intent, legal fees incurred in relation to the US Proceedings and alleged indirect consequential losses Coventry claims it has incurred due to not being able to conclude the transaction with EEA Inc., being, in aggregate, between c.US\$40 million and c.US\$100 million plus alleged punitive damages and interest. In addition to damages, Coventry is seeking an order that EEA Inc. be required to sell (to Coventry) some or all of the Fund's portfolio.

f. Why have redemptions of Shares been suspended?

As noted in the Fund's update to Shareholders on 31 March 2023, there are a number of issues which the Board is currently reviewing as matters of priority, including, among other matters, the US Proceedings. These matters could have implications that might affect the Company and its Shareholders.

Redemptions have been suspended in accordance with the constitutional documentation and scheme particulars for the Fund.

Whilst the Fund is not a party to the US Proceedings, it is implicit that if the assets of its indirect subsidiary, EEA Inc., were reduced by an adverse judgment which is not otherwise covered by insurance, then the value of the Fund's investment into EEA Inc. would also be correspondingly reduced.

g. How long is the suspension redemptions expected to last?

It is the Board's intention that the suspension should run for the shortest possible time. The Board is currently unable to confirm the expected duration of the suspension, although it is likely to run until at least the handing down of the next substantive judgment by the US court, the timing of which cannot currently be estimated.

As noted to Shareholders previously, the Board is reviewing options to improve the net returns on the Fund's cash holdings.

- h. Can Shareholders still submit redemption requests during the suspension? If so, will the quarterly redemption dates remain in place for the purposes of any “queue” that builds up?**

Yes, redemption requests may still be submitted as normal.

Redemption requests will be logged in order that they are received and will be queued by reference to the quarterly redemption date in respect of which they have been received.

- i. What is the potential impact on Shareholders of an adverse judgment?**

Please refer to (d) and (e) above.

If the assets of EEA Inc. were to be reduced by an adverse judgment which is not otherwise covered by insurance, there would be a corresponding reduction to the net asset value of the Fund.

If the net asset value of the Fund is reduced, the value of Shareholders' individual investments in the Fund will also be reduced.

- j. In the case of an adverse judgment, would some or all of the remaining policies in the portfolio need to be sold or transferred to Coventry?**

The Board does not believe it is useful to hypothesise in these Q&As about the possible formulation of any adverse judgment which could be awarded, although this is one of the remedies being sought by Coventry. The formulation of any adverse judgment would be at the discretion of the US courts and until such judgment is made it is not possible to assess any potential reduction in value which could be passed to Shareholders.

- k. In the case of an adverse judgment which requires some or all of the policies comprising the portfolio to be sold or transferred to a third party, how would the remaining policies in the portfolio be valued? Could there be a discrepancy as between how the policies might be valued in such circumstances and how they are currently valued?**

The Board would anticipate that all policies would be valued on a consistent basis in accordance with past practice.

- l. In terms of the Fund's cash holdings, do the US Proceedings cover such amounts and does Coventry have any possible claim against such amounts held by the Fund?**

Please refer to (d), (e) and (h) above.

The Fund is not a party to the US Proceedings or any other proceedings connected to Coventry. Therefore, an adverse judgment against the Fund (including its cash holdings) under the US Proceedings as currently constituted would not be possible.

m. General

The actions taken by the Board to suspend redemptions and the commentary above should not be interpreted as an acceptance or otherwise of the merits of any claim made in the US Proceedings.

As Shareholders will appreciate, it is incumbent on the Board to act prudently and in the best interests of the Fund and Shareholders as a whole, and to limit the Fund's existing and potential exposure to the US Proceeding.

17. What is the latest Update on proposed rollover into a new closed-ended fund to be admitted to trading on the London Stock Exchange?

As noted to Shareholders in the Shareholder Updates, the Proposals are conditional on a number of factors, including obtaining the necessary regulatory approvals required to implement the Proposals.

The Board has decided to pause work on the Proposals. This decision has not been taken lightly and we apologise for the ongoing uncertainty which this creates for Shareholders.

The considerations leading to the decision to pause work on the Proposals are complex but broadly include the following areas, being: (i) the uncertainty created by the ongoing litigation with Coventry (the "Coventry Litigation"); (ii) recent large maturities; (iii) the regulatory approvals which are required to proceed with the Proposals; and (iv) the continuing ability of the Fund to bring the scheme of arrangement which forms part of the Proposals to the Royal Court in Guernsey, taking into account the foregoing.

The Board is unable to comment in detail on the Coventry Litigation as it is ongoing; however, we refer Shareholders to Q.16 for the background to the Coventry Litigation.

In addition, the required regulatory approvals for the New Fund would require strong evidence of the increase in value to Shareholders of the Proposals. Indeed, the Board continues to believe that the successful implementation of the Proposals would likely be beneficial to Shareholders by providing the opportunity to exit their shareholdings in the secondary market. *(The secondary market is a market which exists in an investment after it has been issued – in this case, the secondary market refers to the market in the shares in the New Fund which will exist and be facilitated by admission to trading on the LSE.)*

However, the Board has always been pro-active in assessing Shareholder value and recent improved liquidity within the Fund has narrowed the gap between the value to Shareholders of the Proposals, and the value that might be achieved through continued operation of the Fund while streamlining the Fund's structure. It is anticipated that such streamlining of the Fund's structure would remove all non-essential fees and expenses. The Board is actively investigating the relative merits of this alternative option now, with a view to maximising value for the Fund and Shareholders as a whole.

While each option will have benefits, risks, and drawbacks, we are currently assessing all options and we are working to formalise a plan to achieve the best outcomes for the Fund and its Shareholders as a whole.

The Board is of the view that the only viable options at this point are to progress with the Proposals which will provide potential secondary market liquidity options or to start

streamlining the Fund in order to maximise returns to Shareholders as the Fund's portfolio matures.

18. When will further information become available?

We understand that Shareholders may have questions in relation to this letter. If you do wish to ask a question, please email eea@apexgroup-fs.com. Please note that the Fund's resources are currently directed towards determining the optimum path forward for the Fund – accordingly, the Board thanks Shareholders for their patience in this respect.

The Board will update Shareholders on the matters referred to in this letter as soon as practicable.

19. How can I keep up to date with the Fund?

The Manager provides Shareholders and their advisers with information regarding the Fund at www.eeafmg.com and will continue to do so. This includes monthly Fact Sheets, quarterly Portfolio Statistics (which includes the latest update on performance and maturity projections), the Q&A document, Maturity Schedules, and other Fund updates.